Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health GroupHKSE:08225 Median PS Value is HK$0.17 as of Aug. 26, 2026. The stock has 4 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, China Health Group ranks better than 83.33% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for China Health Group's Median PS Value or its related term are showing as below:
HKSE:08225'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31 Med: 0.84 Max: 4.83
Current: 0.48
During the past 13 years, the highest Price to Median PS Value of China Health Group was 4.83. The lowest was 0.31. And the median was 0.84.
HKSE:08225's Price-to-Median-PS-Value is ranked better than 83.33% of 90
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.91
vs HKSE:08225: 0.48
China Health Group (HKSE:08225) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
China Health Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.081
/
0.17
=
0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Group Median PS Value Related Terms
China Health Group Median PS Value Historical Data
* Premium members only.
The historical data trend for China Health Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08225 vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, China Health Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Health Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where China Health Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 5.3125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Health Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.032.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Group (HKSE:08225) has a Median PS Value of HK$0.17 as of Aug. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Health Group and its competitors. According to the industry distribution chart, China Health Group ranks #15 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is China Health Group's Median PS Value too high?
China Health Group's current Median PS Value is HK$0.17. Based on the distribution chart, China Health Group ranks #15 out of 90 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does China Health Group's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Health Group ranks #15 out of 90 companies for Median PS Value. This places China Health Group in the top 17% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.91, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on China Health Group and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Group's current Median PS Value is HK$0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:08225) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.21, compared to a current price of HK$0.08 — trading 61.4% below its estimated fair value. The current Median PS Value is HK$0.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For China Health Group (HKSE:08225), the current Median PS Value is HK$0.17 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China Health Group Inc is an investment holding company engaged in providing medical care facilities in the People's Republic of China. The company provides provision of post-launch market research, medical and medical market services (PM services), Provision of contracted pharmaceutical development services (PD services), Provision of contracted clinical research services (CR Services), drug technologies, and Other medical services. The majority of its revenue for the company comes from the provision of PM services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08225 has been successfully added to your 
